Cytokine Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 89.58 Billion |
| Market Size (2029) | USD 129.83 Billion |
| CAGR (2024 - 2029) | 7.70 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cytokine Market Analysis
The Global Cytokine Market size is estimated at USD 89.58 billion in 2024, and is expected to reach USD 129.83 billion by 2029, growing at a CAGR of 7.70% during the forecast period (2024-2029).
Globally, COVID-19 had a huge and unprecedented impact on public health and healthcare across several countries. As per the article published in 2021 under the title 'COVID-19 infection: an overview on cytokine storm and related interventions', acute respiratory distress syndrome (ARDS) and pneumonia are the most common outcomes of COVID-19. One of the main causes of death in COVID-19 patients, ARDS is mostly brought on by a cytokine storm, which is an accumulation of pro-inflammatory cytokines. Through the defects of the respiratory epithelium, interleukins, such as interleukin-6 (1L-6), interleukin-1 (IL-1), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-), play a very major role in lung injury in ARDS patients. Hence, as per the factors quoted above, COVID-19 had a significant impact on the cytokine market.
Cytokines are molecular messengers that allow the cells of the immune system to communicate with one another, to generate a coordinated, robust, but self-limited response to a target antigen. There are two types of cytokines used to treat patients with cancer, namely, interferons (INFs) and interleukins (ILs). Cytokines are finding increasing acceptance in cancer therapy over the world. Moreover, cytokines are accepted as biomarkers for disease diagnosis boosting the market growth. For instance, as per the article published in 2022 under the title 'Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis', the serum levels of IL6 and IL10 cytokines on day zero were significantly increased in patients with invasive aspergillosis (IA) when compared to controls even in those who were neutropenic. Furthermore, a study titled 'Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study' published in 2022 stated that cytokine IL-22 is likely to be a biomarker of treatment response to TNF-i and IL-17-i in patients with psoriatic arthritis (PsA).
The presence of competitors, mergers, acquisitions, and research and development in the field of cytokine boost the market growth. For instance, in September 2020 Scientists at Sanford Burnham Prebys Medical Discovery Institute received a USD 3 million grant from the National Institutes of Health (NIH) to study how SARS-CoV-19 weakens the immune system and identify drugs to help infected individuals recover. The major goal of the study is to learn how the coronavirus inactivates the antiviral cytokine pathways.
Hence as per the factors mentioned above cytokine market is expected to witness growth over the forecast period. However, factors such as the high costs of therapy and lack of specificity restrain the market growth.
Cytokine Market Trends
Cancer Segment is Expected to Hold the Largest Share of the Market Over the Forecast Period
The mixture of cytokines that are produced in the cancer microenvironment has an important role in cancer pathogenesis. Cytokines that are released in response to infection, inflammation, and immunity can function to inhibit cancer development and progression. Alternatively, cancer cells can respond to host-derived cytokines that promote growth, attenuate apoptosis, and facilitate invasion and metastasis. To circumvent these impediments, cytokines have been investigated clinically with new engineered cytokine mutants (superkines), chimeric antibody-cytokine fusion proteins (immunokines), anticancer vaccines, checkpoint inhibitors, and cancer-directed monoclonal antibodies to increase their antibody-dependent cellular cytotoxicity or sustain cellular responses and anticancer efficacy.
Factors such as the increased prevalence of cancer, research, and funding in the field of cancer therapy fuel market growth. For instance, as per the Globocan 2020, the number of new cancer cases reported was 19,292,789. This count is expected to rise to 28,887,940 by 2040. Moreover, the presence of competitors, product launches, collaborations, and pipeline assets and research boost market growth. For instance, in April 2022, Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs, published their data from preclinical studies of the company's proprietary Fully-Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022.
Hence, owing to the above-mentioned factors cancer application segment is expected to drive the segment growth over the forecast period.
North American Region Holds the Largest Market Share of the Cytokine Market
North America is anticipated to dominate the cytokine market, due to the rising prevalence of cancer, product launches, and research and development initiatives in the region. For instance, as per the report from Globocan 2020, in the United States, 2,556,022 people were affected with cancer and this figure is expected to rise to 3,316,283 by 2035. The rise in cancer cases is anticipated to boost market growth over the forecast period.
The presence of competitors, mergers, acquisitions and research funding in the studies region boost the market growth. For instance, in June 2022, California based- Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. RIABNI is already approved for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (also called Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). Moreover, in March 2022, Xenco, a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases presented preclinical data from XmAb Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022. Thus increased studies and research related to cytokine amplify the market growth in the studied region.
Hence as per the factors mentioned above, North America is expected to witness growth over the forecast period.
Cytokine Industry Overview
The cytokine market consists of several major players. The companies are implementing certain strategic initiatives, such as a merger, new product launches, acquisitions, and partnerships, which help them in strengthening their market position. Some of the major competitors are Sanofi, AbbVie Inc, UCB S.A, Novartis AG, and Pfizer Inc. among others.
Cytokine Market Leaders
-
Sanofi
-
AbbVie Inc
-
UCB S.A
-
Novartis AG
-
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Cytokine Market News
- In May 2022, Sanofi announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults with prurigo nodularis, a chronic inflammatory skin disease that causes extreme itch and skin lesions. The target action date for the FDA decision is September 30, 2022. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
- In July 2022, Sandoz, a global leader in generic and biosimilar medicines, announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics License Application (sBLA) for a high concentration formulation of 100 mg/mL (HCF) of its biosimilar Hyrimoz (adalimumab-adaz). The application includes the indications of the reference medicine Humira (adalimumab) not protected by orphan exclusivity, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
Cytokine Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increased Acceptance in Cancer Therapy
- 4.2.2 Use of Cytokine as a Potential Biomarker for Neonatal Sepsis
- 4.2.3 Potential Contribution in Stem Cell Therapy
-
4.3 Market Restraints
- 4.3.1 High Costs for Therapy
- 4.3.2 Lacks Specificity
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Cytokine Type
- 5.1.1 Tumor Necrosis Factor-TNF
- 5.1.2 Interleukins-Il
- 5.1.3 Interferons-IFN
- 5.1.4 Epidermal Growth Factor-EGF
- 5.1.5 Other Cytokine Types
-
5.2 By Therapeutic Application
- 5.2.1 Cancer
- 5.2.2 Asthma and Airway Inflammation
- 5.2.3 Arthritis
- 5.2.4 Other Therapeutic Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 GlaxoSmithkline PLC
- 6.1.2 Novartis AG
- 6.1.3 Amgen
- 6.1.4 Pfizer Inc.
- 6.1.5 Sanofi SA
- 6.1.6 AstraZeneca plc
- 6.1.7 Biocon Limited
- 6.1.8 Abbvie Inc
- 6.1.9 Johnson and Johnson
- 6.1.10 UCB S.A
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCytokine Industry Segmentation
As per the scope of the report, cytokines are molecular messengers that allow the cells of the immune system to communicate with one another to generate a coordinated, robust but self-limited response to a target antigen. The multi-faceted applications of cytokines in various domains, like prophylactic, diagnostic, and therapeutic uses, to cure various diseases, have widened the horizons of the cytokine market, globally. The Cytokine Market is segmented by Cytokine Type (Tumor Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other Cytokine Types), Therapeutic Application (Cancer, Asthma and Airway Inflammation, Arthritis, and Other Therapeutic Applications), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Cytokine Type | Tumor Necrosis Factor-TNF | |
| Interleukins-Il | ||
| Interferons-IFN | ||
| Epidermal Growth Factor-EGF | ||
| Other Cytokine Types | ||
| By Therapeutic Application | Cancer | |
| Asthma and Airway Inflammation | ||
| Arthritis | ||
| Other Therapeutic Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Cytokine Market Research FAQs
How big is the Global Cytokine Market?
The Global Cytokine Market size is expected to reach USD 89.58 billion in 2024 and grow at a CAGR of 7.70% to reach USD 129.83 billion by 2029.
What is the current Global Cytokine Market size?
In 2024, the Global Cytokine Market size is expected to reach USD 89.58 billion.
Who are the key players in Global Cytokine Market?
Sanofi, AbbVie Inc, UCB S.A, Novartis AG and Pfizer Inc. are the major companies operating in the Global Cytokine Market.
Which is the fastest growing region in Global Cytokine Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Cytokine Market?
In 2024, the North America accounts for the largest market share in Global Cytokine Market.
What years does this Global Cytokine Market cover, and what was the market size in 2023?
In 2023, the Global Cytokine Market size was estimated at USD 82.68 billion. The report covers the Global Cytokine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Cytokine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cytokine Industry Report
Statistics for the 2024 Cytokine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cytokine analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
